Precigen, Inc. (PGEN) investor relations documents from the company's IR site: 2 presentations, 6 press releases; latest deck 2026-01-15. Read in-app with summaries. First-party data.
Precigen_JPM Healthcare Conference_January 2026_vF.pdf: Precigen's PAPZIMEOS, the first FDA-approved therapy for RRP, launched in 2025, targeting a $1B+ peak revenue market.
| Published | Type | Document |
|---|---|---|
| 2026-08-04 | Press release | Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth |
| Press release | Precigen Reports First Quarter 2026 Financial Results and Business Updates | |
| Press release | Precigen Reports Full Year 2025 Financial Results and Business Updates | |
| 2026-01-15 | Presentation | Precigen_JPM Healthcare Conference_January 2026_vF.pdf |
| Press release | Precigen Reports Third Quarter 2025 Financial Results and Business Updates | |
| Press release | Press release | |
| 2025-08-18 | Presentation | PAPZIMEOS Approval Call_Precigen_August 2025_FINAL.pdf |
| 2020-03-02 | Press release | Dec 8, 2019 61st ASH Annual Meeting & Exposition |
PGEN overview · PGEN earnings · PGEN financials · PGEN KPIs · PGEN documents · PGEN ownership · PGEN peers
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.